Room temperature stable MVA-GP pox vectored vaccine against CCHF

室温稳定的 MVA-GP 痘载体 CCHF 疫苗

• 批准号: 972225
• 金额: $ 54.62万
• 依托单位: NOVA BIOPHARMA TECHNOLOGIES LTD
• 依托单位国家: 英国
• 项目类别: Small Business Research Initiative
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=972225
• 关键词: Room; temperature; stable; MVA; GP

The objective of the proposed programme is to achieve a room-temperature stable, ready-to-inject vaccine against Crimean-Congo haemorrhagic fever (CCHF). HydRIS (Hypodermic Re-hydration Injection System) stabilisation platform with a proven track record of successfully stabilising live viral and bacterial vectors will be assessed to stabilise MVA-GP vaccine- a novel pox-vector based vaccine against CCHF developed by the Health Protection Agency. The successful completion of the programme will enable to develop a CCHF vaccine that will not rely on the cold-chain-distribution, which is especially challenging in certain parts of the world vulnerable to CCHF. As a platform technology, this programme will further demonstrate the applicability to a range of MVA-vectored vaccines. Nova Biopharma Technologies part of Nova Group continue to develop cutting edge technologies supported by it's advanced manufacturing capabilities for both clinical and commercial manufacturing scales. PHE exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. It does this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. PHE is an operationally autonomous executive agency of the Department of Health. PHE Porton undertakes basic and applied research into understanding infectious diseases, with expertise in high containment pathogens. PHE Porton specialise in translational research to develop and test interventions for public health, including new products such as vaccines and diagnostics.

拟议计划的目标是获得一种室温稳定的、即用型克里米亚-刚果出血热（CCHF）注射疫苗。HydRIS（皮下补液注射系统）稳定平台具有成功稳定活病毒和细菌载体的良好记录，将被评估用于稳定MVA-GP疫苗-一种由健康保护局开发的针对CCHF的新型痘病毒载体疫苗。该计划的成功完成将使我们能够开发出一种不依赖冷链配送的CCHF疫苗，而冷链配送在世界上某些易受CCHF影响的地区尤其具有挑战性。作为一项平台技术，该计划将进一步证明其适用于一系列MVA载体疫苗。Nova Bioburma Technologies是Nova集团的一部分，在其先进的临床和商业生产能力的支持下，继续开发尖端技术。PHE的存在是为了保护和改善国家的健康和福祉，减少健康不平等。它通过世界一流的科学、知识和情报、宣传、伙伴关系和提供专业公共卫生服务来做到这一点。公共卫生和环境部是卫生部的一个自主运作的执行机构。PHE Porton从事基础和应用研究，以了解传染病，具有高遏制病原体的专业知识。PHE Porton专注于转化研究，以开发和测试公共卫生干预措施，包括疫苗和诊断等新产品。